Delivery Order SPE2DB22D3016-SPE2DB25FBCH2
- Not listed
- The Defense Logistics Agency awarded a $26,543.31 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 mL pens (2 mL units). This firm fixed-price contract, which carries no set-aside designation, is classified as a delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters, with an ultimate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,219.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 25, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a $68,986.58 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order represents a firm fixed price transaction under an existing Indefinite Delivery Contract vehicle. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $46,237.16. This firm fixed-price delivery order, with an ultimate completion date of July 31, 2025, represents a competitively awarded, non-set-aside procurement executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $20,305.35 to AmerisourceBergen Drug Corp for Dupixent 200 mg/1.14 ml pen injectors on August 7, 2025, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price delivery order represents a single pharmaceutical procurement under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract carries no set-aside designation and is being performed at...
- The Defense Logistics Agency awarded a $3,600.92 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,447.52 for Dupixent 300 mg/2 ml pen (2 ml) on August 13, 2025, with completion targeted for August 14, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 pharmaceutical prime vendor agreement running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $61,377.37 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 21, 2025, with completion targeted for July 22, 2025. This non-set-aside contract represents a child delivery order executed under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. Dupixent is a specialty...
- The Defense Logistics Agency awarded a $14,796.38 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 ml pens. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a specialty biologic medication used to treat conditions including moderate-to-severe atopic...
- The Defense Logistics Agency awarded a delivery order valued at $3,418.92 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectables on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and is being fulfilled from AmerisourceBergen's place of business in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBCH2Delivery Order
The Defense Logistics Agency awarded a $16,218.65 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside, firm fixed-price contract represents a pediatric or adult pharmaceutical delivery under the company's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. Dupixent (dupilumab) is a monoclonal antibody used in treating moderate-to-severe atopic dermatitis, eczema, asthma, and chronic rhinosinusitis with nasal polyps, making this delivery critical for military healthcare beneficiaries requiring specialized immunological treatment. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen Drug Corp's comprehensive pharmaceutical prime vendor agreement with DLA, which establishes the company as a key distributor for military medical supply chains globally. AmerisourceBergen's federal contract portfolio demonstrates extensive experience delivering brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical devices across multiple therapeutic domains. The Defense Logistics Agency utilizes such prime vendor contracts to ensure reliable access to critical pharmaceutical products supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. DLA Troop Support is advancing toward next-generation Pharmaceutical Prime Vendor Global Program Generation V contracts with plans for multiple regional awards across several contractors, reflecting strategic diversification of the federal pharmaceutical supply base.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.2k | 7/18/25 |